Vitiligo - Pipeline Review, H2 2016

Date: October 26, 2016
Pages: 57
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: V73FE93DDA5EN
Leaflet:

Download PDF Leaflet

Vitiligo - Pipeline Review, H2 2016
Vitiligo - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vitiligo - Pipeline Review, H2 2016, provides an overview of the Vitiligo (Dermatology) pipeline landscape.

Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair and eyes. Symptoms include premature whitening or graying of the hair on scalp, eyelashes, eyebrows or beard, loss of color in the tissues that line the inside of mouth and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vitiligo - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vitiligo (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vitiligo (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively for Vitiligo.

Vitiligo (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vitiligo (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Vitiligo (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vitiligo (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vitiligo (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vitiligo (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vitiligo (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vitiligo (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Vitiligo Overview
Therapeutics Development
Pipeline Products for Vitiligo - Overview
Vitiligo - Therapeutics under Development by Companies
Vitiligo - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Vitiligo - Products under Development by Companies
Vitiligo - Companies Involved in Therapeutics Development
Ache Laboratorios Farmaceuticos S/A
Biocon Limited
Bristol-Myers Squibb Company
Clinuvel Pharmaceuticals Limited
Vitiligo - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abatacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACH-24 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
afamelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VLRX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vitiligo - Dormant Projects
Vitiligo - Product Development Milestones
Featured News & Press Releases
Dec 03, 2015: Positive preliminary results in Singaporean vitiligo study
Dec 03, 2015: Update on North American vitiligo program for SCENESSE
May 05, 2015: Clinuvel announces innovative melanocortin for new indications
Mar 20, 2015: SCENESSE vitiligo data presented at world’s largest dermatology conference
Sep 19, 2014: SCENESSE vitiligo study results published in JAMA Dermatology
May 06, 2014: Clinuvel’s Phase II vitiligo study commences in Singapore
Mar 20, 2014: SCENESSE data to feature at American Academy of Dermatology
Nov 04, 2013: Clinuvel to start a Phase II vitiligo study in Singapore
Sep 02, 2013: Five month study follow up shows SCENESSE combination treatment provided stable repigmentation in vitiligo patients
Mar 01, 2013: SCENESSE data to be presented at American Academy of Dermatology, San Gallicano Rare Disease conference
Dec 19, 2012: Clinuvel Pharma Announces Results From Phase IIa Pilot Study Of Scenesse In Vitiligo
Oct 16, 2012: Observations from Clinuvels US vitiligo study published
Mar 15, 2012: Observations from Clinuvels vitiligo and EPP programs being presented at the
Mar 02, 2011: Clinuvel Announces FDA Approval For Vitiligo Drug Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 57

LIST OF TABLES

Number of Products under Development for Vitiligo, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Vitiligo - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
Vitiligo - Pipeline by Biocon Limited, H2 2016
Vitiligo - Pipeline by Bristol-Myers Squibb Company, H2 2016
Vitiligo - Pipeline by Clinuvel Pharmaceuticals Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Vitiligo - Dormant Projects, H2 2016 42

LIST OF FIGURES

Number of Products under Development for Vitiligo, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Vitiligo - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 64 pages
Neurotec Pharma SL - Product Pipeline Review - 2015 US$ 1,275.00 Nov, 2015 · 24 pages
Wounds - Pipeline Review, H1 2015 US$ 1,600.00 Jun, 2015 · 254 pages
Nausea - Pipeline Review, H1 2014 US$ 1,500.00 May, 2014 · 45 pages

Ask Your Question

Vitiligo - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: